BioMarin Announces Fourth Quarter and Record Full-year 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
BioMarin Pharma (BMRN) Tops Q4 EPS by 17c, Offers FY Guidance
February 26, 2020 4:08 PM ESTBioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of $0.08, $0.17 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $454.4 million versus the consensus estimate of $459.33 million.
GUIDANCE:
BioMarin Pharma sees FY2020 revenue of $1.95-2.05 billion, versus the consensus of $1.95... More
